<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 22, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02442271</url>
  </required_header>
  <id_info>
    <org_study_id>M14-225</org_study_id>
    <nct_id>NCT02442271</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil</brief_title>
  <official_title>An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Treatment-Naïve or Treatment-Experienced Adults in Brazil With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ III)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Brazil: National Committee of Ethics in Research</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3b, open-label, multicenter study to evaluate the proportion of subjects
      achieving sustained virologic response 12 weeks post-treatment (SVR12), in adults with
      genotype 1 (GT1) chronic HCV infection, who received treatment with
      ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of participants achieving sustained virologic response SVR12</measure>
    <time_frame>12 weeks after the last actual dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of participants with HCV RNA &lt; LLOQ 12 weeks post-treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving SVR12</measure>
    <time_frame>12 weeks after the last actual dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of participants achieving SVR12 by fibrosis stage (F3 and F4), prior HCV treatment experience (naïve, or categories of prior Interferon(IFN)-based therapy, and IFN eligibility (ineligible, intolerant, eligible).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in general health-related quality of life using the HCV-Patient Related Outcome (HCV PRO) scores</measure>
    <time_frame>From Day 1 of study to 12 weeks after the last actual dose of the study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>The mean change in HCV PRO scores is assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in general health-related quality of life using the SF36V2 Physical Component Summary (PCS) scores</measure>
    <time_frame>From Day 1 of study to 12 weeks after the last actual dose of the study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>The mean change in SF-36V2 PCS scores is assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in general health-related quality of life using the SF36V2 Mental Component Summary (MCS) scores</measure>
    <time_frame>From Day 1 of study to 12 weeks after the last actual dose of the study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>The mean change in SF-36V2 MCS scores is assessed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Chronic Hepatitis C Infection</condition>
  <arm_group>
    <arm_group_label>Ombitasvir/Paritaprevir/Ritonavir &amp; Dasabuvir w/ or w/o RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin (RBV) for 12 or 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ombitasvir/Paritaprevir/Ritonavir</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Ombitasvir/Paritaprevir/Ritonavir &amp; Dasabuvir w/ or w/o RBV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasabuvir</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Ombitasvir/Paritaprevir/Ritonavir &amp; Dasabuvir w/ or w/o RBV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Ombitasvir/Paritaprevir/Ritonavir &amp; Dasabuvir w/ or w/o RBV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females must be post-menopausal for more than 2 years or surgically sterile or
             practicing acceptable forms of birth control

          -  Males must be surgically sterile or agree to practice acceptable forms of birth
             control

          -  Chronic hepatitis C at screening

          -  Fibrosis stage F3 or greater, documented by acceptable tests

          -  Participants with cirrhosis: Absence of hepatocellular carcinoma (HCC) as indicated
             by acceptable methods

        Exclusion Criteria:

          -  Women who are pregnant or breastfeeding

          -  Positive test result for Hepatitis B surface antigen (HbsAg) or anti-HIV antibody
             positive (HIV Ab)

          -  Use of contraindicated medications within 2 weeks of dosing

          -  Clinically significant abnormalities or co-morbidities

          -  History of solid organ transplant

          -  Abnormal laboratory tests

          -  Current or past clinical evidence of Child-Pugh B or C classification or clinical
             history of liver decompensation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katia Alves, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128884</name>
      <address>
        <city>Botucatu</city>
        <zip>18618-970</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128882</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128891</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128880</name>
      <address>
        <city>Recife</city>
        <zip>50100-130</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128885</name>
      <address>
        <city>Ribeirao Preto</city>
        <zip>14048-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128888</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20270-040</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128889</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20210-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128892</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21941-913</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128886</name>
      <address>
        <city>Salvador</city>
        <zip>40110-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136735</name>
      <address>
        <city>Santos</city>
        <zip>11075-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128879</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04128-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128881</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128883</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128890</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129046</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04231-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129398</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04121-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 10, 2015</lastchanged_date>
  <firstreceived_date>May 11, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Hepatitis C</keyword>
  <keyword>Hepatitis C Treatment Naive</keyword>
  <keyword>Hepatitis C Genotype 1</keyword>
  <keyword>Hepatitis C Treatment Experienced</keyword>
  <keyword>Hepatitis C Virus</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
